Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals (AGIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,564,317
  • Shares Outstanding, K 68,889
  • Annual Sales, $ 117,910 K
  • Annual Income, $ -411,470 K
  • 60-Month Beta 2.09
  • Price/Sales 30.23
  • Price/Cash Flow N/A
  • Price/Book 5.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -1.42
  • Number of Estimates 5
  • High Estimate -1.31
  • Low Estimate -1.60
  • Prior Year -1.87
  • Growth Rate Est. (year over year) +24.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.02 +43.64%
on 05/04/20
54.53 -5.11%
on 05/26/20
+8.19 (+18.81%)
since 04/29/20
3-Month
27.77 +86.29%
on 03/18/20
54.53 -5.11%
on 05/26/20
+4.26 (+8.97%)
since 02/28/20
52-Week
27.77 +86.29%
on 03/18/20
54.68 -5.38%
on 01/22/20
+3.83 (+7.99%)
since 05/29/19

Most Recent Stories

More News
Why Is Agios Pharmaceuticals (AGIO) Up 25.8% Since Last Earnings Report?

Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AGIO : 51.74 (-3.02%)
Agios Presents Updated Data from the Phase 1 Dose-escalation Study of Vorasidenib in Patients with IDH-mutant Non-enhancing Glioma

- Vorasidenib Demonstrated Prolonged Disease Control and Encouraging Preliminary Activity with Median Progression-free Survival of 31.4 Months -

AGIO : 51.74 (-3.02%)
Moving Average Crossover Alert: Agios Pharmaceuticals

Agios Pharmaceuticals, Inc. (AGIO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

AGIO : 51.74 (-3.02%)
Agios Pharmaceut Has Returned 12.2% Since SmarTrend Recommendation (AGIO)

SmarTrend identified an Uptrend for Agios Pharmaceut (NASDAQ:AGIO) on May 12th, 2020 at $46.41. In approximately 2 weeks, Agios Pharmaceut has returned 12.18% as of today's recent price of $52.06.

AGIO : 51.74 (-3.02%)
Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?

Is (AGIO) Outperforming Other Medical Stocks This Year?

AGIO : 51.74 (-3.02%)
Agios Announces Publication of TIBSOVO(R) Phase 3 Data in The Lancet Oncology Demonstrating Significant Improvement in Progression-Free Survival Compared to Placebo in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients

- TIBSOVO Is the First and Only IDH1 Inhibitor to Be Evaluated in a Phase 3 Clinical Trial for IDH1-Mutant Cholangiocarcinoma -

AGIO : 51.74 (-3.02%)
Agios to Present Updated Clinical Proof-of-Concept Data from the Phase 2 Study of Mitapivat in Thalassemia in Oral Presentation at the European Hematology Association Annual Congress

- Data Supporting Utility of TIBSOVO in AML and MDS Also Accepted for Presentation -

AGIO : 51.74 (-3.02%)
Agios to Present Updated Data from the Phase 1 Study of Vorasidenib in Non-enhancing Glioma in Oral Presentation at the American Society of Clinical Oncology Annual Meeting

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that vorasidenib and ivosidenib clinical data will be...

AGIO : 51.74 (-3.02%)
Will Agios Pharmaceuticals Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Agios Pharmaceuticals

AGIO : 51.74 (-3.02%)
Agios Pharmaceut Rises 8.54% on Heavy Volume: Watch For Potential Pullback

Agios Pharmaceut (NASDAQ:AGIO) traded in a range yesterday that spanned from a low of $44.43 to a high of $48.17. Yesterday, the shares gained 8.5%, which took the trading range above the 3-day high...

AGIO : 51.74 (-3.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade AGIO with:

Business Summary

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. It discovers and develops therapeutics in the field of cancer metabolism and inborn errors of metabolism. The Company's products include AG-221, AG-120, enzyme glutaminase and AG-348. Agios Pharmaceuticals, Inc. is based in Cambridge, Massachusetts....

See More

Key Turning Points

2nd Resistance Point 55.11
1st Resistance Point 53.42
Last Price 51.74
1st Support Level 49.97
2nd Support Level 48.21

See More

52-Week High 54.68
Last Price 51.74
Fibonacci 61.8% 44.40
Fibonacci 50% 41.23
Fibonacci 38.2% 38.05
52-Week Low 27.77

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar